

Registered number
09004411

Artemida Pharma Ltd

Filleted Accounts

30 April 2022

Artemida Pharma Ltd**Registered number:** 09004411**Balance Sheet****as at 30 April 2022**

	Notes	2022	2021
		£	£
Fixed assets			
Tangible assets	3	7,735	8,221
Investments	4	151	151
		<u>7,886</u>	<u>8,372</u>
Current assets			
Debtors	5	150,916	185,351
Cash at bank and in hand		181,843	82,903
		<u>332,759</u>	<u>268,254</u>
Creditors: amounts falling due within one year	6	(217,350)	(199,438)
Net current assets		<u>115,409</u>	<u>68,816</u>
Net assets		<u>123,295</u>	<u>77,188</u>
Capital and reserves			
Called up share capital		76	103
Profit and loss account		123,219	77,085
Shareholders' funds		<u>123,295</u>	<u>77,188</u>

The directors are satisfied that the company is entitled to exemption from the requirement to obtain an audit under section 477 of the Companies Act 2006.

The members have not required the company to obtain an audit in accordance with section 476 of the Act.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of accounts.

The accounts have been prepared and delivered in accordance with the special provisions applicable to companies subject to the small companies regime. The profit and loss account has not been delivered to the Registrar of Companies.

Robert Miller

Director

Approved by the board on 29 November 2022

Artemida Pharma Ltd
Notes to the Accounts
for the year ended 30 April 2022

1 Accounting policies

Basis of preparation

The accounts have been prepared under the historical cost convention and in accordance with FRS 102, The Financial Reporting Standard applicable in the UK and Republic of Ireland (as applied to small entities by section 1A of the standard).

Turnover

Turnover is measured at the fair value of the consideration received or receivable, net of discounts and value added taxes. Turnover includes revenue earned from the sale of goods and from the rendering of services. Turnover from the rendering of services is recognised by reference to the stage of completion of the contract. The stage of completion of a contract is measured by comparing the costs incurred for work performed to date to the total estimated contract costs.

Tangible fixed assets

Tangible fixed assets are measured at cost less accumulative depreciation and any accumulative impairment losses. Depreciation is provided on all tangible fixed assets, other than freehold land, at rates calculated to write off the cost, less estimated residual value, of each asset evenly over its expected useful life, as follows:

Fixtures, fittings, tools and equipment	25% on reducing balance
---	-------------------------

Investments

Investments in subsidiaries, associates and joint ventures are measured at cost less any accumulated impairment losses. Listed investments are measured at fair value. Unlisted investments are measured at fair value unless the value cannot be measured reliably, in which case they are measured at cost less any accumulated impairment losses. Changes in fair value are included in the profit and loss account.

Taxation

A current tax liability is recognised for the tax payable on the taxable profit of the current and past periods. A current tax asset is recognised in respect of a tax loss that can be carried back to recover tax paid in a previous period. Deferred tax is recognised in respect of all timing differences between the recognition of income and expenses in the financial statements and their inclusion in tax assessments. Current and deferred tax assets and liabilities are not discounted.

Foreign currency translation

Transactions in foreign currencies are initially recognised at the rate of exchange ruling at the date of the transaction. At the end of each reporting period foreign currency monetary items are translated at the closing rate of exchange. Non-monetary items that are measured at historical cost are translated at the rate ruling at the date of the transaction. All differences are charged to profit or loss.

Pensions

Contributions to defined contribution plans are expensed in the period to which they relate.

2 Employees

2022	2021
Number	Number

Average number of persons employed by the company

5

5

3 Tangible fixed assets

	Plant and machinery etc £
Cost	
At 1 May 2021	22,784
Additions	2,092
At 30 April 2022	24,876
Depreciation	
At 1 May 2021	14,563
Charge for the year	2,578
At 30 April 2022	17,141
Net book value	
At 30 April 2022	7,735
At 30 April 2021	8,221

4 Investments

	Investments in subsidiary undertakings £
Cost	
At 1 May 2021	151
At 30 April 2022	151
Subsidiary Undertakings	

The following were subsidiary undertakings of the Company:

Name	Country of incorporation	Class of share	Holding	Principle activities
Artemida Pharma Europe Ltd	Ireland	100 Ordinary shares of Euro 1 each	100%	Pharma Research Consultancy

The aggregate of the share capital and reserves as at 30 April 2022 and of the profit or loss for the year ended on that date for the subsidiary undertakings were as follows:

Aggregate of shares capital and reserves

5 Debtors	2022	2021
	£	£
Trade debtors	61,079	57,853
Other debtors	89,837	127,498
	<u>150,916</u>	<u>185,351</u>

6 Creditors: amounts falling due within one year	2022	2021
	£	£
Bank loans and overdrafts	2,260	2,614
Trade creditors	34,368	20,284
Amounts owed to group undertakings and undertakings in which the company has a participating interest	44,107	45,931
Taxation and social security costs	108,619	106,705
Other creditors	27,996	23,904
	<u>217,350</u>	<u>199,438</u>

7 Controlling party

The ultimate controlling parties are the Directors jointly.

8 Other information

Artemida Pharma Ltd is a private company limited by shares and incorporated in England. Its registered office is:

Stevenage Bioscience Catalyst
Gunnels Wood Road
Stevenage
Hertfordshire
SG1 2FX

This document was delivered using electronic communications and authenticated in accordance with the registrar's rules relating to electronic form, authentication and manner of delivery under section 1072 of the Companies Act 2006.